The Year Ahead: Hard Times For Indian Generics May Force Switch To Innovation
This article was originally published in PharmAsia News
Paucity of blockbuster off-patent opportunities is pressing Indian drug makers to grab technology-led products or devices to secure future growth.
You may also be interested in...
NEW DELHI - India's Sun Pharmaceutical said it would immediately begin sales of a generic version of Wyeth's heartburn drug Protonix (pantoprazole) in the U.S., a move expected to be matched by Israel's Teva Laboratories for a market estimated at $2.3 billion
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.